|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00750256 |
A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects
Condition | Intervention | Phase |
Anemia |
Drug: GSK1278863A |
Phase I |
MedlinePlus related topics: | Anemia |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Placebo Control, Single Group Assignment, Safety Study |
Official Title: | A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects |
Estimated Enrollment: | 36 |
Study Start Date: | July 2008 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Female subjects are eligible for participation in the study if they are of:
Exclusion Criteria:
United States, Indiana | |||||
GSK Clinical Trials Call Center | Recruiting | ||||
Evansville, Indiana, United States, 47710 | |||||
Contact: Stewart Smith 877-379-3718 |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials Call Centre, MD, PhD | GlaxoSmithKline |
Study ID Numbers: | PHX111427 |
First Received: | September 9, 2008 |
Last Updated: | September 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00750256 |
Health Authority: | United States: Food and Drug Administration |
|
|